The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Open accessAbstract
BACKGROUND: Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function. Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease, and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM) that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men. GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation. METHODS: A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women. The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry, and secondary endpoints included physical function, body weight, insulin resistance, and safety. RESULTS: GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful. There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo). The incidence of adverse events was similar between treatment groups. CONCLUSION: GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention and/or treatment of muscle wasting associated with cancer and other chronic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early trials demonstrated a greater total lean mass of 1.3 kg (P < 0.001), better physical function as measured by reduced stair climb time (P = 0.013), a trend towards lower blood levels of glucose of 6.9 ± 2.5 mg/dl (P = 0.052) and lower insulin sensitivity (−27.5% versus 2.6%; P = 0.013) with 3 mg per day of GTx-024 (an orally bioavailable nonsteroidal SARM) than with placebo429.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [429]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Enobosarm significantly increased lean mass compared with baseline (1.0 kg, 95% CI −4.8 to 11.5; P = 0.046) versus controls (0.02 kg, 95% CI −5.8 to 6.7; P = 0.88).”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [429]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Enobosarm, a non-steroidal SARM, successfully increased muscle mass and physical function in patients without cancer and in those with advanced lung, colorectal or breast cancer or lymphoma427–429.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [429]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is some evidence supporting enobosarm’s efficacy for lean mass preservation in elderly men and women [48].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“Selective androgen receptor modulators (SARMs), such as enobosarm (GTx-024), increase lean mass and may improve function, but phase III results have been mixed and no agent has regulatory approval for sarcopenia [71].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [71]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“estimates that 13–24% of persons under the age of 70 and up to 50% of individuals over the age of 80 suffer from significant muscle loss [8].”
BackgroundPrado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMEN
FERRIMAN, D., & GALLWEY, J. D. (1961) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-21-11-1440 · Cited by 2,506
Prognostic effect of weight loss prior tochemotherapy in cancer patients
Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., et al. (1980) · The American Journal of Medicine · doi:10.1016/s0149-2918(05)80001-3 · Cited by 2,354
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Hughes, V. A., Frontera, W. R., Roubenoff, R., Evans, W. J., & Singh, M. A. F. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.2.473 · Cited by 804
Skeletal muscle loss: cachexia, sarcopenia, and inactivity
Evans, W. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.28608a · Cited by 723
Research works printed but not linked: 1
- 10.1002/1097-0142(20010915)92:6 <1669::AID-CNCR1495>3.0.CO;2-S · doi:10.1002/1097-0142(20010915)92:6
Cited by
Cruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Dent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Maltais, F., Decramer, M., Casaburi, R., Barreiro, E., Burelle, Y., Debigaré, R., Dekhuijzen, P. N. R., Franssen, F., Gayan-Ramirez, G., Gea, J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201402-0373st · Cited by 1,090
Self-citation
Metadata
- Authors
- Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S.
- Affiliations
- GTx (United States) (US)
- Corresponding author
- Dalton, James T.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2011-08-02
- Volume
- 2
- Issue
- 3
- Pages
- 153-161
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- PMC
- PMC3177038
- OpenAlex
- W2020213864
- Cited by
- 403
- References
- 40
- Citations by year
- 2026: 29 · 2025: 33 · 2024: 24 · 2023: 28 · 2022: 29 · 2021: 30 · 2020: 30 · 2019: 27 · 2018: 30 · 2017: 29 · 2016: 29 · 2015: 18 · 2014: 32 · 2013: 19 · 2012: 11
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
- Locations
- Journal of Cachexia Sarcopenia and Muscle (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- enobosarm, selective androgen receptor modulators, lean body mass, muscle atrophy, cachexia, physical function, insulin resistance, older men, postmenopausal women, dose-dependent effects, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial. https://app.cochat.ai/papers/10.1007/s13539-011-0034-6
- The paper
- Dalton, J. T., Barnette, K. G., Bohl, C. E., Hancock, M. L., Rodriguez, D., Dodson, S. T., Morton, R. A., & Steiner, M. S. (2011). The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1007/s13539-011-0034-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.